Paul Miller - Synlogic Chief Scientific Officer
| SYBX Stock | USD 1.87 0.04 2.09% |
Executive
Paul Miller is Chief Scientific Officer of Synlogic since 2017.
| Tenure | 7 years |
| Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 401 9975 |
| Web | https://www.synlogictx.com |
Synlogic Management Efficiency
The company has return on total asset (ROA) of (0.3699) % which means that it has lost $0.3699 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9146) %, meaning that it created substantial loss on money invested by shareholders. Synlogic's management efficiency ratios could be used to measure how well Synlogic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.8 in 2024. Return On Capital Employed is likely to rise to -0.95 in 2024. At this time, Synlogic's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 12.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 23.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Soojin Kim | Inozyme PharmaInc | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Gayle Gironda | Inozyme PharmaInc | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Philippa Keith | Terns Pharmaceuticals | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 43 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.37 |
Synlogic Leadership Team
Elected by the shareholders, the Synlogic's board of directors comprises two types of representatives: Synlogic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synlogic. The board's role is to monitor Synlogic's management team and ensure that shareholders' interests are well served. Synlogic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synlogic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Gengos, COO - Head of Corporate Development | ||
| Mylene Perreault, VP Research | ||
| Antoine Awad, Chief Officer | ||
| JoseCarlos GutierrezRamos, Advisor | ||
| Paul Miller, Chief Scientific Officer | ||
| Elizabeth Wolffe, Head Communications | ||
| James Collins, CoFounder Board | ||
| Brendan Amant, General Secretary | ||
| Molly Harper, Chief Officer | ||
| Casi DeYoung, Chief Business Officer | ||
| David Hava, Chief Officer | ||
| Michael Powell, Chairman of the Board | ||
| Mary Dooley, Head Officer | ||
| Ajay Munshi, Vice Development | ||
| Patricia Hurter, Independent Director | ||
| Adam Thomas, Chief Officer | ||
| Michael Jensen, Chief Officer | ||
| Caroline Kurtz, Chief Officer | ||
| Todd Shegog, CFO, Secretary | ||
| Jay Stoudemire, Vice President - Preclinical Development, Regulatory and Quality Assurance | ||
| BAO BCh, CEO Pres | ||
| Edward Mathers, Independent Director | ||
| Aoife Brennan, Chief Medical Officer | ||
| Jose GutierrezRamos, President CEO, Director | ||
| Neal MD, VP Clinical |
Synlogic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Synlogic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (3.84) % | ||||
| Current Valuation | (8.23 M) | ||||
| Shares Outstanding | 11.65 M | ||||
| Shares Owned By Insiders | 15.69 % | ||||
| Shares Owned By Institutions | 70.46 % | ||||
| Number Of Shares Shorted | 35.58 K | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 6.46 X |
Currently Active Assets on Macroaxis
When determining whether Synlogic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Synlogic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Synlogic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Synlogic Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Synlogic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Synlogic Stock please use our How to Invest in Synlogic guide.Note that the Synlogic information on this page should be used as a complementary analysis to other Synlogic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Synlogic Stock analysis
When running Synlogic's price analysis, check to measure Synlogic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synlogic is operating at the current time. Most of Synlogic's value examination focuses on studying past and present price action to predict the probability of Synlogic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synlogic's price. Additionally, you may evaluate how the addition of Synlogic to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Synlogic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Synlogic. If investors know Synlogic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Synlogic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.81) | Revenue Per Share 0.518 | Quarterly Revenue Growth 25.123 | Return On Assets (0.37) | Return On Equity (0.91) |
The market value of Synlogic is measured differently than its book value, which is the value of Synlogic that is recorded on the company's balance sheet. Investors also form their own opinion of Synlogic's value that differs from its market value or its book value, called intrinsic value, which is Synlogic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Synlogic's market value can be influenced by many factors that don't directly affect Synlogic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Synlogic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Synlogic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Synlogic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.